Orion and Abzena Collaborate on New Monoclonal Antibody
Orion and Abzena Collaborate on New Monoclonal Antibody
Recently, Abzena, a prominent contract development and manufacturing organization (CDMO) specializing in complex biologics, shared exciting news about a new partnership with Orion. This collaboration involves an exclusive commercial license for a monoclonal antibody (mAb) specifically engineered to target a challenging cancer type that currently exhibits a significant unmet need in the medical community.
Strengthening Oncology Development Pipeline
This innovative antibody is set to bolster Orion's extensive oncology research and development (R&D) pipeline. The antibody's creation took place at Abzena's state-of-the-art facility using their advanced Composite Human Antibody (CHAb™) technology. This technology forms part of an integrated developability platform that ensures a well-selected lead candidate for development.
Design and Development Process
The selection process was thorough; Abzena's scientists evaluated various antibody candidates against critical success parameters, including functionality, safety, and manufacturability. This screening allowed the team to identify a lead candidate that minimizes potential risks associated with downstream development and enhances clinical outcomes.
Robust Manufacturing Capabilities
Moreover, the collaboration benefits from Abzena's proprietary AbZelectPRO™ cell line development (CLD) platform. This platform has enabled the creation of a highly stable and productive manufacturing cell line designed specifically for the new antibody. The capabilities for large-scale manufacturing will significantly contribute to meeting the demands of clinical development.
Expert Insights
Campbell Bunce, the Chief Scientific Officer of Abzena, expressed enthusiasm about the collaboration, noting, "We are delighted to have partnered with Orion on the design and development of our CHAb-designed mAb to support their extensive oncology-focused Research and Development pipeline. Using our uniquely integrated developability approach along with our streamlined AbZelectPRO™ CLD platform, we were able to design a de-risked lead antibody that offers Orion's program the best chances of success in the clinic."
Antti Haapalinna, Vice President of External Science and Partnering at Orion, shared positive sentiments, highlighting the productive collaboration, stating, "We are very satisfied with the excellent and transparent collaboration and the results it has delivered in our common antibody program." This mutual recognition underscores the strength and efficacy of their partnership.
About Abzena
Abzena stands out as a leader in end-to-end bioconjugates and complex biologics development. They specialize in a fully integrated suite of services, from initial discovery to commercial launch. With a focus on minimizing risk and streamlining processes, Abzena adapts its strategies to each project, facilitating biotechnology and pharmaceutical companies in maximizing their molecules' potential.
The company operates research, development, and cGMP facilities in major locations, including the United States and the United Kingdom. Their robust infrastructure allows them to conduct downstream process development and scaled-up production processes efficiently.
About Orion
Orion is a well-respected Nordic pharmaceutical company with a legacy of over a century dedicated to enhancing well-being globally. The company specializes in the development, manufacturing, and marketing of both human and veterinary pharmaceuticals along with active pharmaceutical ingredients.
Orion boasts an extensive array of proprietary and generic medicines, especially within the domains of oncology and pain management. Its proprietary products are pivotal in treating various health conditions, including cancer and respiratory diseases. In recent financial metrics, Orion reported net sales reaching EUR 1,542 million, employing around 3,700 professionals dedicated to advancing health care globally.
Frequently Asked Questions
What is the focus of the collaboration between Orion and Abzena?
The collaboration focuses on the development and licensing of a monoclonal antibody aimed at tackling a specific type of cancer with high clinical unmet needs.
What technology does Abzena use in this partnership?
Abzena employs its proprietary Composite Human Antibody (CHAb™) technology and the AbZelectPRO™ cell line development platform to enhance the development process.
What benefits does Abzena's platform offer to the antibody project?
Abzena's platforms ensure a robust and de-risked lead antibody candidate, facilitating smoother clinical outcomes and increased chances of success for Orion's oncology pipeline.
How does Orion contribute to this partnership?
Orion leverages its existing research and development infrastructure in oncology to maximize the potential of the newly licensed antibody.
What is the significance of this partnership for future cancer treatments?
This partnership marks a significant collaboration that could lead to improved treatment options for patients facing challenging cancers, enhancing the overall oncology landscape.
About The Author
Contact Lucas Young privately here. Or send an email with ATTN: Lucas Young as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.